A phase I–II trial of cisplatin, hyperthermia and radiation in patients with locally advanced malignancies
✍ Scribed by Terence S Herman; Maxine S Jochelson; Beverly A Teicher; Pamela J Scott; Jorgen Hansen; John R Clark; M.Raphael Pfeffer; Lise E Gelwan; Beverly J Molnar-Griffin; Suzette M Fraser; Goran Svennson; Bruce A Bornstein; L Ryan; C.Norman Coleman
- Publisher
- Elsevier Science
- Year
- 1989
- Tongue
- English
- Weight
- 911 KB
- Volume
- 17
- Category
- Article
- ISSN
- 0360-3016
No coin nor oath required. For personal study only.
📜 SIMILAR VOLUMES
Eighteen patients with advanced malignancies refractory to other forms of treatment were given dactinomycin (Act D) as continuous intravenous infusions. Their median age was 51 years (range, 36-67); their median performance status was 50 (range, 40-90) on the Karnofsky scale. Act D was administered
## Background: Traditionally, primary surgical therapy is considered unsuitable for the treatment of patients with locally advanced breast carcinoma (labc). multiple reports have documented the efficacy of primary chemotherapy in this group of patients. the purpose of this study was to investigate
## Abstract ## BACKGROUND Five randomized studies have demonstrated a benefit derived from adding cisplatin (CDDP)‐based chemotherapy to radiotherapy (RT) for treatment of cervical carcinoma. The Dutch Phase III pelvic tumor trial demonstrated a survival and local control benefit due to the additi
BACKGROUND. This pilot project was undertaken to evaluate the toxicity of and tumor response to combined 13'1 anti-carcinoembryonic antigen monoclonal antibody ('"I anti-CEA RMoAb) and hyperthermia in patients with metastatic colorectal adenocarcinoma.